US Patent Application No: 2003/0157,117

Number of patents in Portfolio can not be more than 2000

Novel method for down-regulation of amyloid

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are novel methods for combatting diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protien (APP) or beta amyloid (A.beta.). Immunization is preferably effected by administration of analogues of autologous APP or A.beta., said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous A.beta. which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Also disclosed are nucleic acid vaccination against APP or A.beta. and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
H. LUNDBECK A/SVALBY-COPENHAGEN376

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Degan, Florence Dal Horsholm, DK 4 17
Jensen, Martin Roland Holte, DK 13 52
Koefoed, Peter Horsholm, DK 6 32
Nielsen, Klaus Gregorius Søborg, DK 22 120
Rasmussen, Peter Birk Copenhagen, DK 28 111

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (4)
8,697,082 Prevention and treatment of synucleinopathic and amyloidogenic disease 0 2004
8,506,959 Prevention and treatment of synucleinopathic and amyloidogenic disease 1 2005
8,147,833 Prevention and treatment of synucleinopathic and amyloidogenic disease 2 2008
8,092,801 Prevention and treatment of synucleinopathic and amyloidogenic disease 3 2008
 
ABBVIE INC. (3)
8,691,224 Anti-Aβ globulomer 5F7 antibodies 0 2006
8,497,072 Amyloid-beta globulomer antibodies 0 2006
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies 0 2007
 
NOVARTIS AG (2)
8,460,676 Composition comprising VLP and amyloid beta peptide 0 2010
8,617,566 Composition comprising VLP and amyloid beta peptide 0 2013
 
ELAN PHARMACEUTICALS, LLC (1)
8,673,593 Antibodies to alpha-synuclein 0 2011
 
H. LUNDBECK A/S (1)
7,135,181 Method for down-regulation of amyloid 9 2001
 
INTEZYNE TECHNOLOGIES, INC. (1)
7,618,944 Encapsulated amyloid-beta peptides 8 2008
 
SIEMENS AKTIENGESELLSCHAFT (1)
7,850,973 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease 0 2006
 
UNIVERSITY OF SOUTH FLORIDA (1)
8,188,046 Amyloid beta peptides and methods of use 0 2007